FDA Prioritizes Review of Sarclisa for Newly Diagnosed Multiple Myeloma Patients

FDA Prioritizes Review of Sarclisa for Newly Diagnosed Multiple Myeloma Patients

By, Admin 29 May 2024

FDA Prioritizes Review of Sarclisa for Newly Diagnosed Multiple Myeloma Patients Excluded from Transplant Eligibility

Overview

The U.S. Food and Drug Administration (FDA) has given priority review status to the Supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for treating newly diagnosed multiple myeloma patients ineligible for transplantation. This combination could potentially be the first of its kind, paving the way for a new treatment avenue for these patients. The FDA is expected to announce its decision on September 27, 2024. A similar submission is also being considered in the European Union (EU).

New First-Line Therapies

  • Sanofi, expressed confidence in Sarclisa's potential, stating that despite recent advancements, there's still a significant need for new first-line therapies, particularly for patients ineligible for transplantation. 
  • He emphasized that the regulatory acceptance of their submissions and the priority review designation from the FDA reinforce their belief in Sarclisa's potential to advance multiple myeloma treatment.

Behind Approval

  • The application for supplemental license and EU approval is based on positive outcomes from the phase III clinical trial IMROZ. 
  • This trial showed a statistically significant improvement in progression-free survival among newly diagnosed multiple myeloma patients ineligible for transplantation who received Sarclisa in combination with VRd chemotherapy compared to those treated with VRd alone. 
  • Safety assessments indicated consistency with established safety profiles.

IMROZ Trial

  • The IMROZ trial is the fourth phase III investigation of Sarclisa paired with VRd chemotherapy in newly diagnosed multiple myeloma patients ineligible for transplantation. 
  • The results of this trial will be presented at major congresses.

Priority Review Designation

Priority review designation is given to drug applications with the potential to significantly advance the treatment of serious diseases.

The IMROZ trial enrolled 446 patients across multiple centers globally. Patients received Sarclisa in combination with VRd chemotherapy until disease progression or unacceptable adverse events.

Sarclisa

  • Sarclisa is a monoclonal antibody targeting the CD38 receptor on multiple myeloma cells, inducing cytotoxic activities and immunomodulation.
  • Sarclisa has received approvals in multiple countries for various combinations in relapsed and refractory multiple myeloma patients. Its clinical development is ongoing in multiple myeloma and other cancers.

Multiple myeloma :- Multiple myeloma is a significant hematologic cancer with a high incidence rate and challenges in treatment and prognosis.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!